United States-based VBI Vaccines has collaborated with United Kingdom-based GlaxoSmithKline to clinically assess the combination of VBI-1901, VBI's cancer vaccine immunotherapeutic, with GSK's proprietary AS01B adjuvant system, it was reported yesterday.
Under the partnership, VBI Vaccines is planning to add an additional study arm to Part B of the company's ongoing Phase 1/2a clinical study targeting recurrent glioblastoma, a cytomegalovirus-associated tumour.
In Part A of the study, the product adjuvanted with granulocyte-macrophage colony-stimulating factor was well-tolerated at all doses, while three out of six patients in a high-dose (10 µg) cohort showcased evidence of stable disease by magnetic resonance imaging that correlated with vaccine-induced immune response. The high-dose has been identified as the optimal therapeutic dose to test in the Part B extension phase of the study. Part B of the ongoing Phase 1/2a clinical study is now planned to be a two-arm, open-label study, enrolling 20 first-recurrent GBM patients to receive VBI-1901 in combination with either GM-CSF or AS01B as immunomodulatory adjuvants.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma